Sifting through countless of stocks in the Pharmaceuticals industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in Organon & Co. or Jazz Pharmaceuticals plc because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.

Read on to learn how Organon & Co. and Jazz Pharmaceuticals plc compare based on key financial metrics to determine which better meets your investment needs.

About Organon & Co. and Jazz Pharmaceuticals plc

Organon & Co. develops and delivers women health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, China, Latin America, the Middle East, Russia, Africa, and internationally. The company's women’s health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, Marvelon, and Mercilon, which are daily pills used to prevent pregnancy; Follistim AQ, which is used to promote the development of multiple ovarian follicles in medically assisted reproduction procedures; Elonva, a follicle stimulant; Ganirelix acetate injection, an injectable antagonist; Jada for abnormal postpartum uterine bleeding and hemorrhage; and Xaciato for bacterial vaginosis. Its biosimilars portfolio consists of immunology products, such as Brenzys, Renflexis, and Hadlima; oncology products, including Ontruzant and Aybintio; Bildyos and Bilprevda, a recombinant anti-RANKL human monoclonal antibodies; and Poherdy, a neu receptor antagonist. The company also offers cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Inegy, Atozet, Rosuzet, and Zocor brands; Cozaar and Hyzaar for hypertension; respiratory products used to control and prevent asthma-induced symptoms under the Singulair, Dulera, Zenhale, and Asmanex brands, as well as seasonal allergic rhinitis under the Nasonex, Clarinex, and Aerius brands. In addition, it provides dermatology products under the Vtama, Diprosone, and Elocon brand; bone health products under the Fosamax brand; and non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brands, as well as Proscar for symptomatic benign prostatic hyperplasia; and Propecia for male pattern hair loss. The company serves drug wholesalers and retailers, hospitals, clinics, government agencies, health maintenance organizations, pharmacy benefit managers, and other institutions. Organon & Co. was founded in 1923 and is headquartered in Jersey City, New Jersey.

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC); Rylaze for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Zepzelca for the treatment of metastatic small cell lung cancer with disease progression on or after platinum-based chemotherapy; Ziihera to treat HER2-positive biliary tract cancers; Modeyso for the treatment of diffuse midline glioma harboring an H3 K27M mutation; and Defitelio to treat severe veno-occlusive disease. It also develops Zanidatamab in Phase 3 trial to treat HER2-positive gastroesophageal adenocarcinoma (GEA) and biliary tract cancers (BTC); Dordaviprone to treat H3 K27M-mutant diffuse glioma; and Vyxeos for the treatment of newly-diagnosed therapy-related acute myeloid leukemia. In addition, the company is developing Zanidatamab to treat neoadjuvant and adjuvant breast cancer; Vyxeos for the treatment of High-risk MDS, newly diagnosed untreated patients with high-risk AML, and De novo intermediate or adverse risk AML stratified by genomics; and JZP3507 to treat pheochromocytoma and paraganglioma that are in Phase 2 clinical trials. Further, it develops JZP815 to treat Raf and Ras mutant tumors; JZP898 for the IFN INDUKIN molecule in solid tumors; and JZP047 to treat absence epilepsy that are in Phase 1 clinical trials. The company has licensing and collaboration agreements with Redx Pharma plc, Autifony Therapeutics Limited, Zymeworks Inc., Sumitomo Pharma Co., Ltd., and Werewolf Therapeutics, Inc. Jazz Pharmaceuticals plc was founded in 2003 and is headquartered in Dublin, Ireland.

Latest Pharmaceuticals and Organon & Co., Jazz Pharmaceuticals plc Stock News

As of April 17, 2026, Organon & Co. had a $2.5 billion market capitalization, compared to the Pharmaceuticals median of $568.2 million. Organon & Co.’s stock is up 36.1% in 2026, up 10.5% in the previous five trading days and down 11.67% in the past year.

Currently, Organon & Co.’s price-earnings ratio is 13.6. Organon & Co.’s trailing 12-month revenue is $6.2 billion with a 3.0% net profit margin. Year-over-year quarterly sales growth most recently was -5.3%. Analysts expect adjusted earnings to reach $3.469 per share for the current fiscal year. Organon & Co. currently has a 0.8% dividend yield.

As of April 17, 2026, Jazz Pharmaceuticals plc had a $12.5 billion market cap, putting it in the 81st percentile of all stocks. Jazz Pharmaceuticals plc’s stock is up 19.7% in 2026, up 4.7% in the previous five trading days and up 97.67% in the past year.

Currently, Jazz Pharmaceuticals plc does not have a price-earnings ratio. Jazz Pharmaceuticals plc’s trailing 12-month revenue is $4.3 billion with a -8.3% net profit margin. Year-over-year quarterly sales growth most recently was 10.1%. Analysts expect adjusted earnings to reach $24.057 per share for the current fiscal year. Jazz Pharmaceuticals plc does not currently pay a dividend.

How We Compare Organon & Co. and Jazz Pharmaceuticals plc Stock Grades

Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.

AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at Organon & Co. and Jazz Pharmaceuticals plc’s stock grades to see how they measure up against one another.

Learn more about A+ Investor here!

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

Organon & Co. and Jazz Pharmaceuticals plc Growth Grades

Company	Ticker	Growth
Organon & Co.	OGN	D
Jazz Pharmaceuticals plc	JAZZ	A

The foundation of growth investing is seeking out stocks of companies exhibiting strong, consistent and prolonged growth that is expected to continue into the future.

In order to compute the growth score and assign it a letter grade, the percentile ranks for each of three components‐consistency of annual sales growth, five-year sales growth rankings adjusted for extreme levels, and consistency of positive annual cash from operations‐must be determined. These three rank figures are added together, and the sum is ranked against the entire stock universe to arrive at a company’s Growth Score to create an equal distribution of grades.

The companies in the bottom 20% of the stock universe receive Growth Grades of F, considered to be very weak, while those in the top 20% receive A grades, which are considered very strong.

Organon & Co. has a Growth Score of 25, which is Weak. Jazz Pharmaceuticals plc has a Growth Score of 89, which is Very Strong.

The Growth Grade Winner: Jazz Pharmaceuticals plc

As you can clearly see from the Growth Grade breakdown above, Jazz Pharmaceuticals plc has a more attractive growth grade than Organon & Co.. For investors who focus solely on how a company is growing relative to other companies in the same industry, Jazz Pharmaceuticals plc could be a good stock to add to their portfolio. However, it’s important for investors to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Organon & Co. and Jazz Pharmaceuticals plc’s Quality Grades

Company	Ticker	Quality
Organon & Co.	OGN	B
Jazz Pharmaceuticals plc	JAZZ	A

Like the Value Grade, AAII’s A+ Investor Quality Grade comes from the percentile rank of key metrics. Specifically, the Quality Score is the percentile rank of the average of the percentile ranks of return on assets (ROA), return on invested capital (ROIC), gross profit relative to assets, buyback yield, change in total liabilities to assets, accruals, Z double prime bankruptcy risk (Z) score and the F-Score.

The score is variable, meaning it can consider all eight measures or, should any of the eight measures not be valid, the remaining measures that are valid. To be assigned a Quality Score, stocks must have a valid (non-null) measure and corresponding ranking for at least four of the eight quality measures.

The Quality Score is used to assess the underlying “quality” of a particular stock. A higher-quality stock possesses traits associated with upside potential and reduced downside risk. Backtesting of the Quality Grade shows that stocks with higher grades, on average, outperformed stocks with lower grades over the period of 1998 through 2019.

Stocks receive better grades (higher scores) for having higher scores for the quality subcomponents and worse grades (lower scores) for lower scores for the subcomponents.

Organon & Co. has a Quality Score of 72, which is Strong. Jazz Pharmaceuticals plc has a Quality Score of 82, which is Very Strong.

The Quality Grade Winner: Jazz Pharmaceuticals plc

As you can clearly see from the Quality Grade breakdown above, Jazz Pharmaceuticals plc has a better overall quality grade than Organon & Co.. For investors who are looking for companies with higher quality than others in the same industry, Jazz Pharmaceuticals plc could be a good stock to add to their portfolios. However, it’s important for investors to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Organon & Co. and Jazz Pharmaceuticals plc’s Momentum Grades

Company	Ticker	Momentum
Organon & Co.	OGN	D
Jazz Pharmaceuticals plc	JAZZ	A

Momentum grades help to uncover stocks experiencing anomalously high rates of return; research finds that stocks with high relative levels of momentum tend to outperform, whereas those with low levels of momentum tend to continue underperforming. Momentum is based on the price change of a stock over a specified period relative to all other stocks.

Typically, AAII looks at the weighted relative strength over the trailing four quarters. The weighted four-quarter relative strength rank is the relative price change for each of the past four quarters. The most recent quarterly price change is given a weight of 40% and each of the three previous quarters are given a weighting of 20%.

Organon & Co. has a Momentum Score of 35, which is Weak. Jazz Pharmaceuticals plc has a Momentum Score of 82, which is Very Strong.

The Momentum Grade Winner: Jazz Pharmaceuticals plc

As you can clearly see from the Momentum Grade breakdown above, Jazz Pharmaceuticals plc is considered to have stronger momentum compared to Organon & Co.. For those specifically looking for companies that have stronger momentum compared to other companies in the same industry, Jazz Pharmaceuticals plc could be a good stock to invest in. However, it’s important for investors to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Other Organon & Co. and Jazz Pharmaceuticals plc Grades

In addition to Momentum, Growth and Quality, A+ Investor also provides grades for Value and Estimate Revisions.

Earnings estimate revisions scores take into account the magnitude of a company’s earnings surprise in its last two reported fiscal quarters. Often, surprises beget further surprises‐or at least continued sales growth (the exact opposite is generally true, too).

Successful stock investing involves buying low and selling high, so stock valuation is an important consideration for stock selection. Buying stocks that are going to go up typically means buying stocks that are undervalued in the first place, although momentum investors may argue that point.

These 2 key factors, when combined with the above, provide a holistic view into a particular stock. Further, by joining A+ Investor you can see whether Organon & Co. and Jazz Pharmaceuticals plc pass any of our 60+ stock screens that have outperformed the market since their creation.

So, Which Is the Better Investment, Organon & Co. or Jazz Pharmaceuticals plc Stock?

Overall, Organon & Co. stock has a Growth Score of 25, Momentum Score of 35 and Quality Score of 72.

Jazz Pharmaceuticals plc stock has a Growth Score of 89, Momentum Score of 82 and Quality Score of 82.

Comparing Organon & Co. and Jazz Pharmaceuticals plc’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as your risk tolerance and financial goals to see if either of these stocks would make a good fit for you. AAII can help you figure out which investments align with your individual needs and preferences.

Investors are encouraged to do their own due diligence and research. In this way, individuals can effectively become managers of their own assets‐without having to rely on others for financial independence. You can count on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis.

A+ Investor adds to our qualitative teaching with a powerful data suite to help you whittle down investment choices to find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs.

AAII Disclaimer

We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown, because past, hypothetical or simulated performance is not necessarily indicative of future results. Before making an investment decision, you should consider your circumstances and whether the information on our content is applicable to your situation. This information was prepared in good faith, and we accept no liability for any errors or omissions. The full disclaimer can be read here.